Can vaccination of all adults slow down the second wave?

It is very much possible to slow down the pace of virus spread by vaccinating all above 18 years. However, with vaccine shortage in many States, the number of daily vaccinations in the last week has been dipping. Since April 1 the number daily fresh cases has been accelerating rapidly with the number of cases … Continue reading Can vaccination of all adults slow down the second wave?

How can India contain the second wave?

In a conversation I moderated, Dr. Gautam Menon, Professor of Physics and Biology at Ashoka University and Dr. Giridhara Babu, epidemiologist at the Public Health Foundation of India, Bengaluru and a member of the Karnataka COVID-19 Technical Advisory Committee discuss some possible options available to contain the second wave. Edited excerpts: After daily new COVID-19 … Continue reading How can India contain the second wave?

In a major shift, India fast-tracks restricted use approval for vaccines developed in other countries

On April 13, India permitted fast-track approval of COVID-19 vaccines developed, tested and approved outside the country. The decision has been taken to “expand the basket of vaccines for domestic use and hasten the pace and coverage” of COVID-19 vaccination. But before mass roll out of the vaccines that are developed and tested abroad can … Continue reading In a major shift, India fast-tracks restricted use approval for vaccines developed in other countries

SEC allows Bharat Biotech to unblind all participants above 45 years

The Subject Expert Committee (SEC) has permitted Bharat Biotech to unblind all phase-3 trial participants above 45 years and offer the vaccine to those who received a placebo. The reason: vaccines (including Covaxin) are already available under the immunisation programme, and therefore all the eligible age groups should be unblinded for vaccination.

Interim phase-3 trial results show Sputnik V vaccine has 91.6% efficacy

Results of an interim analysis of phase-3 trial of Russia’s Sputnik V vaccine show the vaccine is safe and has 91.6% efficacy. The efficacy against severe disease increased to 100% after 21 days. Although the study was not designed to assess the efficacy of a single dose regimen, the researchers were able to observe a … Continue reading Interim phase-3 trial results show Sputnik V vaccine has 91.6% efficacy

Can COVID-19 vaccines with EUA be used at the population level?

Emergency use approval is given during public health emergencies and that emergency is the same for everyone, countries have identified high-risk groups that will receive the vaccine first. If and when vaccines from many manufacturers become available, can it be used at the population level even when they have only an emergency use approval is … Continue reading Can COVID-19 vaccines with EUA be used at the population level?

Pfizer’s COVID-19 vaccine shows promise, many unknowns remain

The over 90% effectiveness reported is basically against symptomatic infection. But the nature of infection — mild, moderate or severe — that the vaccine can protect against is not clear. It is also unclear if the vaccinated participants have been asymptomatically infected and whether older adults were protected. The first interim analysis of the Phase-3 … Continue reading Pfizer’s COVID-19 vaccine shows promise, many unknowns remain

Scientists alert Lancet to ‘data inconsistencies’ in the Russian vaccine trial paper

A group of 16 scientists has written an open letter to Dr Richard Horton, editor of The Lancet and authors of the Russia's Sputnik V novel coronavirus vaccine trial paper, raising questions about the integrity of the data published in The Lancet on September 4. Just four days after the results of the Phase-1/2 trials … Continue reading Scientists alert Lancet to ‘data inconsistencies’ in the Russian vaccine trial paper